VWF products licensed to treat VWD in the United States
| Product . | Indication . | Dosage (adults)∗ . | Approximate VWF:RCo-to-FVIII ratio in vial . | Reference . |
|---|---|---|---|---|
| Plasma derived | ||||
| Alphanate | Surgical and/or invasive procedures in adult and pediatric patients with VWD in whom DDAVP is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery | Preoperative dose of 60 IU VWF:RCo/kg body weight; subsequent doses of 40-60 IU VWF:RCo/kg body weight. | 1.2:1 | 38,39 |
| Humate P | (1) Treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD as well as patients with mild to moderate VWD in which the use of DDAVP is known or suspected to be inadequate | (Target peak plasma VWF:RCo level – baseline plasma VWF:RCo level)/in vivo recovery in patient × body weight (BW) in kg | 2.4:1 | 40,41 |
| Wilate | (1) On-demand treatment and control of bleeding episodes, (2) perioperative management of bleeding | Required IU = BW in kg × desired VWF:RCo rise (%) (IU/dL) × 0.5 (IU/kg per IU/dL) | 1:1 | 42 |
| Recombinant | ||||
| Vonvendi | (1) On-demand treatment and control of bleeding episodes1 (2) Perioperative management of bleeding1 (3) Routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 VWD receiving on-demand therapy | Give 12-24 h before surgery to allow the endogenous FVIII levels to increase to at least 30 IU/dL (minor surgery) or 60 IU/dL (major surgery) | n/a | 43 |
| Product . | Indication . | Dosage (adults)∗ . | Approximate VWF:RCo-to-FVIII ratio in vial . | Reference . |
|---|---|---|---|---|
| Plasma derived | ||||
| Alphanate | Surgical and/or invasive procedures in adult and pediatric patients with VWD in whom DDAVP is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery | Preoperative dose of 60 IU VWF:RCo/kg body weight; subsequent doses of 40-60 IU VWF:RCo/kg body weight. | 1.2:1 | 38,39 |
| Humate P | (1) Treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD as well as patients with mild to moderate VWD in which the use of DDAVP is known or suspected to be inadequate | (Target peak plasma VWF:RCo level – baseline plasma VWF:RCo level)/in vivo recovery in patient × body weight (BW) in kg | 2.4:1 | 40,41 |
| Wilate | (1) On-demand treatment and control of bleeding episodes, (2) perioperative management of bleeding | Required IU = BW in kg × desired VWF:RCo rise (%) (IU/dL) × 0.5 (IU/kg per IU/dL) | 1:1 | 42 |
| Recombinant | ||||
| Vonvendi | (1) On-demand treatment and control of bleeding episodes1 (2) Perioperative management of bleeding1 (3) Routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 VWD receiving on-demand therapy | Give 12-24 h before surgery to allow the endogenous FVIII levels to increase to at least 30 IU/dL (minor surgery) or 60 IU/dL (major surgery) | n/a | 43 |
n/a, not applicable.
Plasma-derived VWF/FVIII concentrates can be dosed based on the FVIII or VWF in the vial, and it is important to specify that the dosing is given based on the VWF:RCo units in the vial.